Research Triangle Park (RTP) is widely recognized as one of the foremost innovation hubs in the United States. Situated ...

GSK GSK1.94%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning, it’s a busy ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

A few months after appointing a new CEO, a drug developer in Research Triangle Park has made more additions to its leadership team. STORY HIGHLIGHTS Fennec Pharmaceuticals appointed three new C ...